User login
Key clinical point: Aumolertinib vs. gefitinib as the first-line therapy significantly improves progression-free survival (PFS) in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutation (i.e., exon 19 deletion or L858R mutation).
Major finding: The aumolertinib vs. gefitinib group had a significantly longer median PFS (19.3 vs. 9.9 months; hazard ratio [HR] 0.46; P < .0001). The PFS advantage of aumolertinib over gefitinib was substantial in the subgroup of patients with central nervous system metastases (15.3 vs. 8.2 months; HR 0.38; P < .0001).
Study details: This randomized, double-blind, multicenter, phase 3 AENEAS trial included 429 patients with EGFR-mutated NSCLC who were randomly assigned (1:1) to receive either the first-line aumolertinib or gefitinib once daily orally.
Disclosures: The study was funded by Hansoh Pharmaceutical Group Co, Ltd. Many authors reported ties with one or more pharmaceutical companies, including Hansoh Pharma.
Source: Lu S et al. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non–small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 (May 17). Doi: 10.1200/JCO.21.02641
Key clinical point: Aumolertinib vs. gefitinib as the first-line therapy significantly improves progression-free survival (PFS) in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutation (i.e., exon 19 deletion or L858R mutation).
Major finding: The aumolertinib vs. gefitinib group had a significantly longer median PFS (19.3 vs. 9.9 months; hazard ratio [HR] 0.46; P < .0001). The PFS advantage of aumolertinib over gefitinib was substantial in the subgroup of patients with central nervous system metastases (15.3 vs. 8.2 months; HR 0.38; P < .0001).
Study details: This randomized, double-blind, multicenter, phase 3 AENEAS trial included 429 patients with EGFR-mutated NSCLC who were randomly assigned (1:1) to receive either the first-line aumolertinib or gefitinib once daily orally.
Disclosures: The study was funded by Hansoh Pharmaceutical Group Co, Ltd. Many authors reported ties with one or more pharmaceutical companies, including Hansoh Pharma.
Source: Lu S et al. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non–small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 (May 17). Doi: 10.1200/JCO.21.02641
Key clinical point: Aumolertinib vs. gefitinib as the first-line therapy significantly improves progression-free survival (PFS) in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) mutation (i.e., exon 19 deletion or L858R mutation).
Major finding: The aumolertinib vs. gefitinib group had a significantly longer median PFS (19.3 vs. 9.9 months; hazard ratio [HR] 0.46; P < .0001). The PFS advantage of aumolertinib over gefitinib was substantial in the subgroup of patients with central nervous system metastases (15.3 vs. 8.2 months; HR 0.38; P < .0001).
Study details: This randomized, double-blind, multicenter, phase 3 AENEAS trial included 429 patients with EGFR-mutated NSCLC who were randomly assigned (1:1) to receive either the first-line aumolertinib or gefitinib once daily orally.
Disclosures: The study was funded by Hansoh Pharmaceutical Group Co, Ltd. Many authors reported ties with one or more pharmaceutical companies, including Hansoh Pharma.
Source: Lu S et al. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non–small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022 (May 17). Doi: 10.1200/JCO.21.02641